Compare 10X Genomics Inc (TXG) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Verizon Communications Inc — how do they compare? 10X Genomics Inc trades at $83.55 (market cap $10.07B), while Verizon Communications Inc trades at $43.09 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 19.1× 10X Genomics Inc's market cap, and Verizon Communications Inc pays a 6.11% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Verizon Communications Inc for 109 Days on average.
| TXG | VZ | |
|---|---|---|
Market Cap | $10.07B | $192.57B |
Volume | 5,657,286 | 20,940,094 |
Sector | Health | Media |
52-Week High | $97.74 | $51.45 |
52-Week Low | $11.48 | $38.40 |
Typical Hold Time | 92 Days | 109 Days |
Enterprise Value | $9.59B | $379.28B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Verizon trades at $45.77, down 0.46% today, with a bearish technical outlook despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.07, ROE of 15.63%, and consistent dividend payments. Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand satellite connectivity and the election of Charles Phillips to the board. Cash flow improved significantly in 2025 with net cash flow of $14.9 billion.
Verizon offers value with reasonable valuation metrics and strong cash flow generation supporting its dividend. However, technical indicators signal bearish momentum, and revenue growth remains modest. The stock faces competitive pressures in the telecom sector and carries substantial long-term debt of $121.38 billion. Analyst consensus is mixed with 37.7% buy ratings but a price target of $48.58 suggesting modest upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
